Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214143 | 0.86 | NPSR1 (0.45) | NPSR1CCR4KDM4EALDH1A1PKM | |
| SCHEMBL20046668 | 0.84 | NPSR1 (0.56) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL3581736 | 0.82 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL29844710 | 0.81 | GRM5 (0.52) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL361702 | 0.81 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL261816 | 0.81 | GRM5 (0.52) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL1475724 | 0.81 | NPSR1 (0.47) | NPSR1CCR4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5274364 | 0.81 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL23214139 | 0.79 | NPSR1 (0.45) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL5274971 | 0.79 | NPSR1 (0.45) | NPSR1KDM4EALDH1A1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | NPSR1 3684/4885CCR4 4622/4885KDM4E 2459/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | NPSR1 2254/4885CCR4 1150/4885KDM4E 4515/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | NPSR1 2680/4885CCR4 1282/4885KDM4E 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.